Deucrictibant, an oral therapy being developed for bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema, has been granted orphan drug status in the European Union. This designation, granted by the European Commission, intends to back the development of therapies to diagnose, prevent, or treat rare…
Keeping symptoms of hereditary angioedema (HAE) under control is the most important factor contributing to a better quality of life, according to a study carried out by scientists reporting from India and noting severe limits on access to first-line medications there. “There is an urgent need for easy availability…
A Phase 3 clinical trial testing sebetralstat as an on-demand treatment for swelling attacks in children with hereditary angioedema (HAE) has completed enrollment a year ahead of schedule. The trial’s initial target enrollment was surpassed in less than seven months, according to KalVista Pharmaceuticals, which is developing…
The symptoms of hereditary angioedema (HAE) can be very hard on adolescents, significantly affecting their health-related quality of life, particularly in regard to schooling and their social and emotional well-being, a U.S. study based on interviews with a dozen young patients reported. Those taking part, ages 12 to 17…
Short-term preventive treatment before dental procedures may not be necessary for people with hereditary angioedema (HAE) who are already on long-term prophylaxis, according to a new study by researchers in Germany. It’s well-established that dental procedures and surgeries can act as triggers to increase the risk of the swelling…
More than half of individuals admitted to an emergency department, or ED, for drug-induced nonallergic angioedema — with nearly all of these patients experiencing swelling as a side effect of medications known as angiotensin-converting enzyme inhibitors, or ACEIs — showed improvement, with most staying briefly and few returning…
Sebetralstat, an oral small molecule being developed by Kalvista Pharmaceuticals, provided adults and adolescents with hereditary angioedema (HAE) with early on-demand treatment for swelling attacks and offered fast symptom relief, even when swelling affected the larynx (voice box). That’s according to interim data from KONFIDENT-S (NCT05505916),…
Astria Therapeutics has initiated a Phase 3 clinical trial to study its experimental therapy navenibart in adults and adolescents with hereditary angioedema (HAE). The study, called ALPHA-ORBIT (NCT06842823), is planned to be pivotal, meaning, if the results are positive, the trial may serve as the basis to…
An oral granule formulation of Orladeyo (berotralstat) was safe and well tolerated, and able to reduce the rates of swelling attacks in children with hereditary angioedema (HAE), according to an interim analysis of an ongoing Phase 3 trial. The open-label Phase 3 APeX-P trial (NCT05453968) is assessing the…
Andembry (garadacimab) is approved in Switzerland as a prophylactic (preventive) treatment to lower the frequency of recurrent swelling attacks in people with hereditary angioedema (HAE), ages 12 and older. The decision by the Swiss Agency for Therapeutic Products marks the fifth regulatory approval of Andembry for HAE, following…
Get regular updates to your inbox.
